Beta Bionics (NASDAQ:BBNX) Insider Mike Mensinger Sells 2,650 Shares of Company Stock

Key Points

• Insider Mike Mensinger sold 2,650 Beta Bionics shares at an average price of $22, generating $58,300. His remaining direct stake was 174,740 shares, and he has made two additional sales recently.
• Beta Bionics shares fell 1.5% to $17.58, with the stock trading well below its 52-week high of $32.71. The company has a market capitalization of approximately $791 million and remains unprofitable.
• Third-quarter results modestly exceeded expectations: the company reported a loss of $0.52 per share versus the expected $0.53 loss and revenue of $35.51 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $23.69.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mike Mensinger sold 2,650 shares of the company's stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00. Following the transaction, the insider directly owned 174,740 shares of the company's stock, valued at $3,844,280. This represents a 1.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 16th, Mike Mensinger sold 2,650 shares of Beta Bionics stock. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00.
• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total value of $83,606.25.

Beta Bionics Stock Down 1.5%

BBNX traded down $0.27 during trading on Thursday, reaching $17.58. 1,288,471 shares of the company's stock were exchanged, compared to its average volume of 1,185,205. The company has a market capitalization of $790.92 million, a P/E ratio of -10.65 and a beta of 3.39. The business has a 50 day moving average price of $19.21 and a 200 day moving average price of $14.90. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.01. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $35.51 million for the quarter. As a group, research analysts forecast that Beta Bionics, Inc. will post -2.02 EPS for the current year.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst support remains favorable. Stifel Nicolaus reiterated its “Buy” rating. The broader analyst consensus remains “Moderate Buy,” with an average price target above the current trading level. Stifel Nicolaus Buy Rating
• Positive Sentiment: Third-quarter results modestly beat expectations. Beta Bionics reported a loss of $0.52 per share versus the expected $0.53 loss, while revenue of $35.51 million exceeded estimates of approximately $34.7 million. The company also updated its full-year 2026 outlook, although the available reports did not provide all guidance details. Beta Bionics Third-Quarter Results
• Neutral Sentiment: Insider selling adds a modest cautionary signal. Director Mark Hopman sold 821 shares for approximately $16,420, reducing his direct ownership by about 1.48%. The sale was relatively small compared with his remaining holdings, but it follows several earlier sales. SEC Insider Filing
• Negative Sentiment: Multiple law firms are publicizing a securities class action. The case covers investors who purchased BBNX securities between July 30, 2025, and February 24, 2026, with a November 3 deadline to seek lead-plaintiff status. Although the allegations remain unproven, the volume of notices increases legal and reputational risk. Beta Bionics Shareholder Lawsuit Alert
• Negative Sentiment: The lawsuit centers on alleged FDA and iLet disclosure issues. Plaintiffs allege that Beta Bionics inadequately disclosed FDA quality-system findings and potentially serious iLet-related complaints. Further regulatory action, product remediation, litigation expenses or damage to customer confidence could weigh on future growth and valuation. Beta Bionics FDA Compliance Lawsuit
• Negative Sentiment: Execution risks could affect the planned Mint patch-pump launch. Investors remain concerned about commercialization, manufacturing and regulatory execution for the company’s next-generation product, potentially limiting the benefit of the quarterly revenue beat. Beta Bionics Mint Pump Execution Risks

Wall Street Analysts Forecast Growth

BBNX has been the topic of several analyst reports. Leerink Partners upped their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, September 14th. Wall Street Zen upgraded shares of Beta Bionics from a "sell" rating to a "hold" rating in a research report on Saturday, September 19th. TD Cowen boosted their price target on shares of Beta Bionics from $18.00 to $21.00 and gave the company a "hold" rating in a research report on Wednesday. William Blair began coverage on shares of Beta Bionics in a research note on Friday, August 21st. They set a "market perform" rating on the stock. Finally, UBS Group restated a "buy" rating and set a $25.00 price target on shares of Beta Bionics in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Beta Bionics has a consensus rating of "Moderate Buy" and an average price target of $23.69.

Institutional Trading of Beta Bionics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Beta Bionics in the 2nd quarter valued at $52,340,000. Eversept Partners LP boosted its holdings in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock valued at $14,177,000 after acquiring an additional 736,576 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company's stock valued at $8,446,000 after acquiring an additional 240,000 shares during the last quarter. Bruce & Co. Inc. bought a new position in Beta Bionics in the first quarter valued at about $5,518,000. Finally, Bank of America Corp DE acquired a new stake in Beta Bionics in the second quarter worth about $8,566,000.

About Beta Bionics

Beta Bionics, Inc NASDAQ: BBNX is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual's glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.